[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].
3/5 보강
TL;DR
A panel of experts convened a panel of experts to critically review methods used for molecular diagnostics and follow-up of patients with CML, define best practices applicable in this context and formulate recommendations.
OpenAlex 토픽 ·
Chronic Myeloid Leukemia Treatments
Acute Myeloid Leukemia Research
Chronic Lymphocytic Leukemia Research
A panel of experts convened a panel of experts to critically review methods used for molecular diagnostics and follow-up of patients with CML, define best practices applicable in this context and form
APA
Jean-Michel Cayuela, Stéphanie Dulucq, et al. (2026). [Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].. Bulletin du cancer, 113(4), 512-532. https://doi.org/10.1016/j.bulcan.2025.05.017
MLA
Jean-Michel Cayuela, et al.. "[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].." Bulletin du cancer, vol. 113, no. 4, 2026, pp. 512-532.
PMID
40908230 ↗
Abstract 한글 요약
Molecular biologists play an important role in therapeutic decisions in the context of Chronic Myelogenous Leukemia (CML). Before treatment, it is mandatory to identify the BCR::ABL1 fusion and any prognostic cytogenetic abnormalities that may be present. During treatment, regular assessment of measurable residual disease (MRD) is essential to objectively evaluate the optimal response and identify situations of resistance to treatment. Monitoring of MRD is also required when considering treatment discontinuations. In cases of resistance, identifying mutations that confer resistance to tyrosine kinase inhibitors is essential for adapting the treatment. The Group of Molecular Biologists of Hematologic Malignancies (GBMHM) and the France Intergroup of Chronic Myeloid Leukemia (Fi-LMC) convened a panel of experts to critically review methods used for molecular diagnostics and follow-up of patients with CML, define best practices applicable in this context and formulate recommendations.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Leukemia
- Myelogenous
- Chronic
- BCR-ABL Positive
- Fusion Proteins
- bcr-abl
- Neoplasm
- Residual
- Protein Kinase Inhibitors
- Drug Resistance
- Mutation
- France
- BCR::ABL1
- CML
- Chronic myeloid leukemia
- Diagnostic moléculaire
- Leucémie myéloïde chronique
- Maladie résiduelle mesurable
- Measurable residual disease
- Molecular diagnostics
- Mutations de résistance
- Mutations of resistance
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.